CytRx (CYTR) Misses Q2 EPS by 8c

CytRx (NASDAQ: CYTR) reported Q2 EPS of ($0.27), $0.08 worse than the analyst estimate of ($0.19).

CytRx reported cash and cash equivalents of $55.9 million as of June 30, 2016. Subsequent to the close of the second quarter, CytRx completed a public offering of common stock and warrants that expire one year from issuance for total net proceeds of approximately $18.3 million.

For earnings history and earnings-related data on CytRx (CYTR) click here.

You May Also Be Interested In

• Etsy upgraded to buy at BofA on durable growth, buyback potential
• Deere shares climb as fiscal Q3 earnings and revenue top estimates
• Jefferies Downgrades Pop Mart International Group Ltd (9992:HK) to Hold